Eli Lilly shares finished the session roughly flat as investors weighed recent regulatory wins against emerging competition in the weight-loss drug market. The company recently secured FDA approval for the expanded use of Olumiant in pediatric patients and received a nod for its once-weekly insulin, Onswik, though these developments were offset by market attention surrounding positive clinical data from smaller competitor Viking Therapeutics. While Wall Street analysts remain largely bullish with an average price target of $1,325, the stock continues to trade within a consolidation phase as the market evaluates the company's long-term growth prospects against its current valuation of 40x earnings.